This independent CME/CE activity is supported by an educational grant from Intercept Pharmaceuticals, Inc.




Chair
faculty image
David E. J. Jones, MD, PhD
  • Professor of Liver Immunology & Hon Consultant Hepatologist
  • NIHR Dean for Faculty Trainees
  • Newcastle University
  • Newcastle upon Tyne, United Kingdom

  • Date:
    Sunday, November 13, 2016
    Time:
    6:30 PM 
    Registration/Dinner 

     
    7:00–8:30 PM 
    Scientific Session 
    Location:
    Sheraton Boston
    Republic Ballroom
    39 Dalton Street
    Boston, MA

    This live symposium has ended.

    Excerpts of the live presentations will be available soon in the form of an on-demand webcast. If you would like to be notified once it is available, please email us at pbcpscBoston@projectsinknowledge.com [Please put "PBC Webcast—Inform Me" in the subject line].

    Presented for attendees of the 67th AASLD Annual Meeting (The Liver Meeting®). This event/function is sponsored by Projects In Knowledge and supported by Intercept Pharmaceuticals, Inc. This is not an official event/function of the American Association for the Study of Liver Diseases.
    AGENDA
    7:00-7:05 pm
    Introduction: PBC, PSC, and the Microbiome
    David E.J. Jones, MD, PhD
    7:05-7:20 pm
    Diagnosing and Profiling the PBC Patient
    Christopher L. Bowlus, MD
    7:20-7:35 pm
    New Strategies for the Treatment and Management of PBC
    David E.J. Jones, MD, PhD
    7:35-7:50 pm
    Medical Management of PSC: Evolving Solutions to Ongoing Challenges
    Michael Trauner, MD
    7:50-8:05 pm
    The Microbiome and Cholestatic Liver Disease
    Gary D. Wu, MD
    8:05-8:25 pm
    Panel: Insights Into Patient Management (Q&A)
    Faculty Panel
    8:25-8:30 pm
    Concluding Remarks
    David E.J. Jones, MD, PhD
    CME/CE Information

    Estimated time for completion of this activity:

    CME: 1.5 hours
    CNE:  1.5 hours
    CPE:  1.5 hours

    Target Audience

    This CME/CE activity is designed for hepatologists, gastroenterologists, infectious disease specialists, primary care providers, nurses, physician assistants, and pharmacists who are involved involved in the screening and treatment of patients with or at risk for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and dysbiosis of the gut/biliary microbiota.

    Activity Goal

    The goal of this activity is to examine and formulate strategies for the diagnosis, treatment, and management of PBC and PSC that result in improved patient outcomes and the role of the microbiome in cholestatic liver disease.

    Learning Objective(s)

    • Describe PBC and PSC, assess the importance of early diagnosis of each and recent advances in our understanding of pathophysiologic mechanisms that may serve as targets for therapy.
    • Analyze criteria for assessing treatment response in both PBC and PSC, and formulate therapeutic treatment interventions to improve patient outcomes.
    • Assess dysbiosis of the gut/biliary microbiota, analyze the importance of early diagnosis, and evaluate what pathophysiologic mechanisms may serve as targets for therapy.


    CME Information: Physicians


    Statement of Accreditation

    Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation

    Projects In Knowledge® designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    CE Information: Nurses

    Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Upon completion of this course, participants will be awarded 1.50 nursing contact hour(s).

    DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, or PIK endorsement of any commercial product or service.

    CE Information: Pharmacists

    Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

    This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This satellite symposium is worth up to 1.5 contact hour(s) (0.15 CEU). The ACPE Universal Activity Number assigned to this Application-type activity is 0052-0000-16-187-L01-P.

    Pharmacists should only claim credit commensurate with the extent of their participation in the activity.

    CME/CE Instructions


    To obtain credit for the live meeting:

    1. Sign in at the registration desk.
    2. Attend the live satellite symposium.
    3. Complete the evaluation form.
    4. Submit it to the event representative as you exit.
    5. Your certificate will be emailed to you within 4 weeks of the activity date.

    There is no fee for this activity.

    CONTRACT FOR MUTUAL RESPONSIBILITY IN CME/CE

    Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

    For more information on the contract, click here.

    Disclosure Information

    The Disclosure Policy of Projects In Knowledge® requires that all those who have control of content comply with the Standards for Commercial Support. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.

    David E. J. Jones, MD, PhD has received honoraria from Falk Pharma; has received consulting fees from Falk Pharma, GlaxoSmithKline, Intercept Pharmaceuticals, and Novartis Pharmaceuticals Corporation; has conducted contracted research for Pfizer Inc; and has ownership interest in AstraZeneca.

    Christopher L. Bowlus, MD has received honoraria from Intercept Pharmaceuticals; received consulting fees from GlaxoSmithKline; and has conducted contracted research from Bristol-Myers Squibb Company, CymaBay Therapeutics, Intercept Pharmaceuticals, Shire, and Takeda Pharmaceuticals Company Limited.

    Michael Trauner, MD has received speakers fees from AbbVie, Falk Pharma, Gilead, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; has received consulting fees from AbbVie, Albireo Pharma, Falk Pharma, Gilead, Intercept Pharmaceuticals, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Novartis Pharmaceuticals Corporation, and Phenex Pharmaceuticals.

    Gary D. Wu, MD has received consulting fees from Chr. Hansen, Janssen Pharmaceuticals, Inc., Nestle, and Pfizer Inc; and has conducted contracted research for Intercept Pharmaceuticals, Seres Therapeutics, and Takeda Pharmaceuticals.

    Peer Reviewer has disclosed no relevant relationships.

    Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no relevant relationships to disclose.
    Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no relevant relationships to disclose.

    Nancy J. Nordenson, MT (ASCP), MFA Medical Writer, has disclosed no relevant relationships.

    Projects In Knowledge's staff members have no relevant relationships to disclose.

    Planning Committee
    Christopher L. Bowlus, MD has received honoraria from Intercept Pharmaceuticals; received consulting fees from GlaxoSmithKline; and has conducted contracted research from Bristol-Myers Squibb Company, CymaBay Therapeutics, Intercept Pharmaceuticals, Shire, and Takeda Pharmaceuticals Company Limited.
    David E. J. Jones, MD, PhD has received honoraria from Falk Pharma; has received consulting fees from Falk Pharma, GlaxoSmithKline, Intercept Pharmaceuticals, and Novartis Pharmaceuticals Corporation; has conducted contracted research for Pfizer Inc; and has ownership interest in AstraZeneca.
    Michael Trauner, MD has received speakers fees from AbbVie, Falk Pharma, Gilead, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; has received consulting fees from AbbVie, Albireo Pharma, Falk Pharma, Gilead, Intercept Pharmaceuticals, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Novartis Pharmaceuticals Corporation, and Phenex Pharmaceuticals.
    Gary D. Wu, MD has received consulting fees from Chr. Hansen, Janssen Pharmaceuticals, Inc., Nestle, and Pfizer Inc; and has conducted contracted research for Intercept Pharmaceuticals, Seres Therapeutics, and Takeda Pharmaceuticals.

    Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

    The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

    This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

    This independent CME/CE activity is supported by an educational grant from Intercept Pharmaceuticals, Inc.

    Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.


    2298 1